Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease

Masatoshi Eto, Masahiko Harano, Katsunori Tatsugami, Mamoru Harada, Yoriyuki Kamiryo, Keijiro Kiyoshima, Masumitsu Hamaguchi, Masazumi Tsuneyoshi, Yasunobu Yoshikai, Seiji Naito

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Much attention has been paid to nonmyeloablative allogeneic stem cell transplantation for the treatment of renal cancer. We recently proposed a cyclophosphamide-using nonmyeloablative cell therapy in which donor lymphocyte infusion (DLI) was carried out after the tolerance induction to donor cells. In considering the clinical application of the cyclophosphamide-using cell therapy, attempts to reduce graft-versus-host disease (GVHD) are crucial. The aim of the present study was to modify the cyclophosphamide-using cell therapy to reduce the risk of GVHD while preserving the antitumor activity against renal cancer. Experimental Design: We assessed whether a delay in performing DLI from day 1 to day 5 after the cyclophosphamide treatment could reduce the risk of GVHD while preserving antitumor activity against RENCA, a murine carcinogen-induced renal cell carcinoma, in the cyclophosphamide-using cell therapy. Results: Regarding the in vivo antitumor effect, there was no difference between DLI on day 1 and day 5 after the cyclophosphamide treatment, whereas the histologic findings of the small intestine showed that the cyclophosphamide-using cell therapy with DLI on day 5 decreased the risk of GVHD. In addition, the acquired immunity against RENCA was also observed in the RENCA-rejected mice that had been treated with DLI on day 5. Conclusions: Our results show that a delay in DLI during cyclophosphamide-using nonmyeloablative cell therapy can dissociate graft-versus-tumor effects from GVHD by reducing the risk of GVHD.

Original languageEnglish
Pages (from-to)1029-1035
Number of pages7
JournalClinical Cancer Research
Volume13
Issue number3
DOIs
Publication statusPublished - Feb 1 2007

Fingerprint

Kidney Neoplasms
Graft vs Host Disease
Cell- and Tissue-Based Therapy
Cyclophosphamide
Lymphocytes
Stem Cell Transplantation
Adaptive Immunity
Renal Cell Carcinoma
Carcinogens
Small Intestine
Research Design
Therapeutics
Transplants

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease. / Eto, Masatoshi; Harano, Masahiko; Tatsugami, Katsunori; Harada, Mamoru; Kamiryo, Yoriyuki; Kiyoshima, Keijiro; Hamaguchi, Masumitsu; Tsuneyoshi, Masazumi; Yoshikai, Yasunobu; Naito, Seiji.

In: Clinical Cancer Research, Vol. 13, No. 3, 01.02.2007, p. 1029-1035.

Research output: Contribution to journalArticle

Eto, Masatoshi ; Harano, Masahiko ; Tatsugami, Katsunori ; Harada, Mamoru ; Kamiryo, Yoriyuki ; Kiyoshima, Keijiro ; Hamaguchi, Masumitsu ; Tsuneyoshi, Masazumi ; Yoshikai, Yasunobu ; Naito, Seiji. / Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 3. pp. 1029-1035.
@article{d85cc92ce2cd4ecba7214fb0c8dc8713,
title = "Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease",
abstract = "Purpose: Much attention has been paid to nonmyeloablative allogeneic stem cell transplantation for the treatment of renal cancer. We recently proposed a cyclophosphamide-using nonmyeloablative cell therapy in which donor lymphocyte infusion (DLI) was carried out after the tolerance induction to donor cells. In considering the clinical application of the cyclophosphamide-using cell therapy, attempts to reduce graft-versus-host disease (GVHD) are crucial. The aim of the present study was to modify the cyclophosphamide-using cell therapy to reduce the risk of GVHD while preserving the antitumor activity against renal cancer. Experimental Design: We assessed whether a delay in performing DLI from day 1 to day 5 after the cyclophosphamide treatment could reduce the risk of GVHD while preserving antitumor activity against RENCA, a murine carcinogen-induced renal cell carcinoma, in the cyclophosphamide-using cell therapy. Results: Regarding the in vivo antitumor effect, there was no difference between DLI on day 1 and day 5 after the cyclophosphamide treatment, whereas the histologic findings of the small intestine showed that the cyclophosphamide-using cell therapy with DLI on day 5 decreased the risk of GVHD. In addition, the acquired immunity against RENCA was also observed in the RENCA-rejected mice that had been treated with DLI on day 5. Conclusions: Our results show that a delay in DLI during cyclophosphamide-using nonmyeloablative cell therapy can dissociate graft-versus-tumor effects from GVHD by reducing the risk of GVHD.",
author = "Masatoshi Eto and Masahiko Harano and Katsunori Tatsugami and Mamoru Harada and Yoriyuki Kamiryo and Keijiro Kiyoshima and Masumitsu Hamaguchi and Masazumi Tsuneyoshi and Yasunobu Yoshikai and Seiji Naito",
year = "2007",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-06-1578",
language = "English",
volume = "13",
pages = "1029--1035",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease

AU - Eto, Masatoshi

AU - Harano, Masahiko

AU - Tatsugami, Katsunori

AU - Harada, Mamoru

AU - Kamiryo, Yoriyuki

AU - Kiyoshima, Keijiro

AU - Hamaguchi, Masumitsu

AU - Tsuneyoshi, Masazumi

AU - Yoshikai, Yasunobu

AU - Naito, Seiji

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Purpose: Much attention has been paid to nonmyeloablative allogeneic stem cell transplantation for the treatment of renal cancer. We recently proposed a cyclophosphamide-using nonmyeloablative cell therapy in which donor lymphocyte infusion (DLI) was carried out after the tolerance induction to donor cells. In considering the clinical application of the cyclophosphamide-using cell therapy, attempts to reduce graft-versus-host disease (GVHD) are crucial. The aim of the present study was to modify the cyclophosphamide-using cell therapy to reduce the risk of GVHD while preserving the antitumor activity against renal cancer. Experimental Design: We assessed whether a delay in performing DLI from day 1 to day 5 after the cyclophosphamide treatment could reduce the risk of GVHD while preserving antitumor activity against RENCA, a murine carcinogen-induced renal cell carcinoma, in the cyclophosphamide-using cell therapy. Results: Regarding the in vivo antitumor effect, there was no difference between DLI on day 1 and day 5 after the cyclophosphamide treatment, whereas the histologic findings of the small intestine showed that the cyclophosphamide-using cell therapy with DLI on day 5 decreased the risk of GVHD. In addition, the acquired immunity against RENCA was also observed in the RENCA-rejected mice that had been treated with DLI on day 5. Conclusions: Our results show that a delay in DLI during cyclophosphamide-using nonmyeloablative cell therapy can dissociate graft-versus-tumor effects from GVHD by reducing the risk of GVHD.

AB - Purpose: Much attention has been paid to nonmyeloablative allogeneic stem cell transplantation for the treatment of renal cancer. We recently proposed a cyclophosphamide-using nonmyeloablative cell therapy in which donor lymphocyte infusion (DLI) was carried out after the tolerance induction to donor cells. In considering the clinical application of the cyclophosphamide-using cell therapy, attempts to reduce graft-versus-host disease (GVHD) are crucial. The aim of the present study was to modify the cyclophosphamide-using cell therapy to reduce the risk of GVHD while preserving the antitumor activity against renal cancer. Experimental Design: We assessed whether a delay in performing DLI from day 1 to day 5 after the cyclophosphamide treatment could reduce the risk of GVHD while preserving antitumor activity against RENCA, a murine carcinogen-induced renal cell carcinoma, in the cyclophosphamide-using cell therapy. Results: Regarding the in vivo antitumor effect, there was no difference between DLI on day 1 and day 5 after the cyclophosphamide treatment, whereas the histologic findings of the small intestine showed that the cyclophosphamide-using cell therapy with DLI on day 5 decreased the risk of GVHD. In addition, the acquired immunity against RENCA was also observed in the RENCA-rejected mice that had been treated with DLI on day 5. Conclusions: Our results show that a delay in DLI during cyclophosphamide-using nonmyeloablative cell therapy can dissociate graft-versus-tumor effects from GVHD by reducing the risk of GVHD.

UR - http://www.scopus.com/inward/record.url?scp=33847371148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847371148&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1578

DO - 10.1158/1078-0432.CCR-06-1578

M3 - Article

C2 - 17289899

AN - SCOPUS:33847371148

VL - 13

SP - 1029

EP - 1035

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -